



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/575, A61K 38/22	A1	(11) International Publication Number: WO 00/05260 (43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/EP99/03020 (22) International Filing Date: 30 April 1999 (30.04.99) (30) Priority Data: 09/119,540 20 July 1998 (20.07.98) US (71) Applicant (for all designated States except US): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A. [FR/FR]; 51-53, rue du Docteur Blanche, F-75016 Paris (FR). (72) Inventor; and (75) Inventor/Applicant (for US only): DONG, Zheng, X. [CN/US]; 40 Angelica Drive, Framingham, MA 01701 (US). (74) Agent: LUNT, Mark, G., F.; Dibb Lupton Alsop, Fountain Precinct, Balm Green, Sheffield S1 1RZ (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PEPTIDE ANALOGUES OF PACAP (57) Abstract The present invention is directed to novel analogues of PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) as described in the specification, which are agonist of the PACAP receptor and as such are useful in treating cerebrovascular ischemia, male impotence, motor neuron disease, neuropathy, pain, depression, anxiety disorders, brain trauma, memory impairments, dementia, cognitive disorder, central nervous system diseases (such as Parkinson's disease, Alzheimer's disease), migraine, neurodegenerative diseases, ischemic heart disease, myocardial infarction, fibrosis, restenosis, diabetes mellitus, muscle disease, gastric ulcer, stroke, atherosclerosis, hypertension, septic shock, thrombosis, retina disease, cardiovascular disease, renal failure and cardiac failure and the prevention of neuronal cell death in a mammal. This invention is also directed to pharmaceutical compositions useful therefor.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PEPTIDE ANALOGUES OF PACAP

Background of the Invention

5 The present invention is directed to novel analogues of PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) and the use thereof for treating the conditions and or diseases as described herein.

 A review of PACAP and its physiological function is summarized in Christophe, J., Biochimica et Biophysica Acta, 1154, 183-199 (1993), as follows.

10 PACAP a member of a super family that already includes several regulatory peptides, e.g., VIP, PHI, PHV, secretin, helodermin, helospectin I and II, glucagon, GIP and GRF. This biologically active neuropeptide exists in two amidated forms: PACAP(1-38)-NH₂ (PACAP-38) and PACAP(1-27)-NH₂ (PACAP-27). The deduced amino acid sequence of PACAP-38 in man (Kimura, C., et al., Biochem. Biophys. Res. Commun., 166, 81-89, (1990)) and rat (Ogi, K., et al., Biochem. Biophys. Res. Commun., 173, 1271-1279, (1990)) is identical to that of the isolated ovine PACAP-38.

 At least two classes of PACAP receptors have been described in mammalian tissues and cell lines: type I PACAP-preferring receptors and type II
20 receptors which bind PACAP-27, PACAP-38 and VIP (vasoactive intestinal peptide) (Cauvin, A., et al., Peptides, 11, 773-777 (1990) and Shivers, B.D., et al., Endocrinology, 128, 3055-3065 (1991)). In addition, the first type is capable to display two subtypes, and the second type can be tentatively divided into three subtypes.

25 Type I is highly selective in that it recognizes PACAP-27 and PACAP-38 much more potently than VIP. PACAP-38 and PACAP-27 can thereafter activate adenylate cyclase with the same high potency and efficacy. Type I receptors may, however, be present as two coexisting subtypes (or states) based on radioligand binding. In rat brain membranes (Cauvin, A., et al., Regul. Pept. 35, 161-173, 30 (1991)), the PACAP-A subtype exhibits hardly any preference for PACAP-38 over

PACAP-27, whereas the PACAP-B subtype recognizes PACAP-38 with high affinity and PACAP-27 with low affinity.

The type II receptor is the classical VIP receptor. Based on binding affinity and adenylate cyclase activation, it now appears that the type II receptor is non-selective since it shows similar high affinity for PACAP-27, PACAP-38 and VIP.

A relatively comprehensive spectrum of pharmacological activities has already been established for the physiological roles of PACAP.

Concerning the hypothalamo-pituitary axis, PACAP reduces food intake in mice and raises plasma arginine vasopressin in rat, probably through PACAP-ir (ir= immunoreactive) neurons in paraventricular and supraoptic nuclei projecting to the neurohypophysis. PACAP originating in the hypothalamus may also be transported to the anterior pituitary through portal vessels. Data on the antehypophysis suggest a role on i.a. reproduction and growth. PACAP stimulates adenylate cyclase and increases $[Ca^{2+}]$ in gonadotropes, somatotropes, and folliculostellate cells. It elevates the secretion of α -MSH from melanotropes, and that of interleukin-6 from pituitary folliculo-stellate cells. PACAP potentiates the effects of LHRH (or GnRH, gonadotropin releasing hormone) on LH (lutening hormone) and FSH secretion. More clearly perhaps, PACAP increases the synthesis of LH, GH (growth hormone), PRL (prolactin) and ACTH after 1-2 days. In human pathology, PACAP-27 and PACAP-38 stimulate adenylate cyclase activity in membranes from "null", gonadotropin-, GH-, and ACTH-producing pituitary adenomas.

In brain, and outside the hypothalamus, PACAP stimulates the synthesis of melatonin from pinealocytes and may play a role in the integration of visual inputs and in memory. The widespread distribution of specific type I PACAP receptors contrasts with the more focused localization of type II VIP-PACAP receptors. Type I receptors in the rabbit eye may contribute to the physiology of the retina and choroid. In general, the neuronal increases in cAMP and Ca^{2+} could contribute to early brain development, repair, and modification of circuitry, with the help of neurotropic factors from astrocytes that are also stimulated by PACAP.

Type I receptors represent a minority (20%) as compared to type II receptors in rat liver. PACAP directly relaxes the digestive tract motility via activation of apamin-sensitive calcium-activated K^+ channels and is an anion secretory neuropeptide on rat jejunal mucosa, possibly through submucous neurons. PACAP contracts the gallbladder in conscious dog by a preganglionic mechanism. *In vivo* it increases amylase secretion via a cholinergic mechanism in dog and glucagon release in mice.

PACAP provokes the hypersecretion and synthesis of catecholamines from the rat adrenal and facilitates mitosis, neurite genesis, and survival of cultured rat sympathetic neuroblasts. A bolus i.v. injection of PACAP induces a biphasic change in blood pressure (decrease followed by increase) that is accompanied by a biphasic change in systemic vascular resistance. The pressor response is due to the release of catecholamines from the adrenal gland. The relaxant action of PACAP in isolated rabbit precontracted aortic rings is 100-fold more potent than VIP, surprisingly durable, and endothelium-independent. PACAP is also a potent microvasodilator in human skin and here its action is long lasting again. PACAP-38 causes an increase in beating rate in neonatal rat cardiomyocytes and stimulates adenylate cyclase in purified sarcolemmal membranes from porcine and canine ventricles. PACAP relaxes the airway and vascular smooth muscle in guinea-pig, rat and cat lung. PACAP-ir is abundant in the rat testis and type I receptors in spermatozoa may play a role in sperm motility.


In addition, PACAP may intervene in ontogenetic processes in the nervous system and modulate mitogenesis and differentiation (e.g., neurite outgrowth) in several cell lines where malignancy is sometimes at the origin of type I receptor emergence.

Therefore, there is a keen interest to find analogues of PACAP which are more active than PACAP-27 and/or PACAP-38 and/or which possess a longer half-life in a patient.

United States Patent No. 5,208,320 discloses certain peptides that produce c-AMP activity. Robberecht, P., et al., Molecular Pharmacology 42:347-355, (1992) discloses a series of PACAP-27 and PACAP-38 analogues. PCT publication no. WO 96/09064 discloses a series of PACAP analogues for use in preventing or treating brain damage.

Summary of the Invention

This invention is directed to a peptide of formula (I),



(I),

or a pharmaceutically acceptable salt thereof, wherein,

A¹ is His or Pal;

A² is Ser, Thr or hSer;

A³ is Asp or Glu;

A⁴ is Gly, β -Ala, Gaba, Ava, Aib, Acc or HN-(CH₂)_m-C(O);

- A^5 is Ile, Leu, Cha, Nle, Val, Tle, Abu, Aib, Acc or Nva;
 A^6 is Phe, p-X-Phe, β -Nal, Cha, Tyr, Trp, Acc or Aib;
 A^7 is Thr, Ser or Val;
 A^8 is Asp or Glu;
 A^9 is Ser, Thr or hSer;
 A^{10} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp or Acc;
 A^{11} is Ser, Thr or hSer;
 A^{12} , A^{14} and A^{15} are each independently selected from the group consisting of Arg, Lys, Orn, hArg and $\text{HN-CH}((\text{CH}_2)_n\text{-NH-R}^4)\text{-C(O)}$;
 A^{13} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp or Acc;
 A^{16} is Gln, Glu, Asp or Asn;
 A^{17} is Met, Leu, Nle, Abu, Tle, Val, Ile, Cha, Ala, Aib, Acc or Nva;
 A^{18} is Ala, Aib or Acc;
 A^{19} is Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Acc, Nle or Nva;
 A^{20} , A^{21} , A^{29} , A^{30} , A^{32} , A^{34} , A^{36} and A^{38} are each independently selected from the group consisting of Lys, Arg, Orn, hArg and $\text{HN-CH}((\text{CH}_2)_n\text{-NH-R}^4)\text{-C(O)}$ or is deleted;
 A^{22} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp, Acc or is deleted;
 A^{23} is Leu, Ile, Nle, Tle, Met, Val, Ala, Aib, Acc, Cha, Phe, p-X-Phe, Abu, Nva or is deleted;
 A^{24} is Ala, Aib, Val, Abu, Acc, Ile, Leu, Nle, Tle, Nva or is deleted;
 A^{25} is Ala, Glu, Aib, Val, Abu, Acc, Ile, Leu, Nle, Nva, Tle or is deleted;
 A^{26} is Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Acc, Nva, Nle or is deleted;
 A^{27} is Leu, Ile, Nle, Tle, Met, Val, Ala, Aib, Acc, Nva, Cha, Phe, p-X-Phe, Abu or is deleted;
 A^{28} is Gly, Aib, Acc, β -Ala, Gaba, Ava, $\text{HN-(CH}_2)_m\text{-C(O)}$ or is deleted;
 A^{31} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp, Acc or is deleted;
 A^{33} is Gln, Asn, Glu, Asp or is deleted;
 A^{35} is Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Nva, Acc, Nle or is deleted;
 A^{37} is Asn, Gln, Asp, Glu, Ala, Aib, Acc or is deleted;
 R^1 and R^2 are each independently selected from the group consisting of H, $(\text{C}_1\text{-C}_{30})$ alkyl, $(\text{C}_2\text{-C}_{30})$ alkenyl, phenyl- $(\text{C}_1\text{-C}_{30})$ alkyl, naphthyl- $(\text{C}_1\text{-C}_{30})$ alkyl, hydroxy- $(\text{C}_1\text{-C}_{30})$ alkyl, hydroxy- $(\text{C}_2\text{-C}_{30})$ alkenyl, hydroxy-phenyl- $(\text{C}_1\text{-C}_{30})$ alkyl or hydroxy-naphthyl- $(\text{C}_1\text{-C}_{30})$ alkyl;
 or one of R^1 or R^2 is COX^2 where X^2 is $(\text{C}_1\text{-C}_{30})$ alkyl, $(\text{C}_2\text{-C}_{30})$ alkenyl, phenyl- $(\text{C}_1\text{-C}_{30})$ alkyl, naphthyl- $(\text{C}_1\text{-C}_{30})$ alkyl, hydroxy- $(\text{C}_1\text{-C}_{30})$ alkyl, hydroxy- $(\text{C}_2\text{-C}_{30})$ alkenyl, hydroxy-phenyl- $(\text{C}_1\text{-C}_{30})$ alkyl or hydroxy-naphthyl- $(\text{C}_1\text{-C}_{30})$ alkyl;

5

R^3 is OH, NH_2 , (C_1-C_{30}) alkoxy or $NH-Y-CH_2-Z$, where Y is a (C_1-C_{30}) hydrocarbon moiety and Z is CO_2H or $CONH_2$;

where X for each occurrence is independently selected from the group consisting of OH, OCH_3 , F, Cl, Br and CH_3 ;

5 m for each occurrence is independently an integer from 5-10;

n for each occurrence is independently an integer from 1-5; and

R^4 for each occurrence is independently (C_1-C_{30}) alkyl, (C_1-C_{30}) acyl or $-C((NH)(NH_2))$.

A preferred group of peptides of formula (I), denoted Group A, are those
10 peptides wherein at least one of A^5 , A^{17} , A^{18} , A^{19} , A^{23} , A^{27} , A^{28} and A^{35} is Acc, or a pharmaceutically acceptable salt thereof.

A preferred group of the Group A peptides, denoted Group B, are those peptides wherein at least one of A^5 , A^{17} , A^{18} , A^{19} , A^{23} , A^{27} , A^{28} and A^{35} is A6c or A5c, or a pharmaceutically acceptable salt thereof.

15 A preferred group of the Group B peptides, denoted Group C, are those peptides wherein at least one of A^5 , A^{18} and A^{19} is A5c, or a pharmaceutically acceptable salt thereof.

A preferred group of the Group B peptides, denoted Group D, are those peptides wherein at least one of A^{17} , A^{19} , A^{23} , A^{27} , A^{28} and A^{35} is A6c, or a
20 pharmaceutically acceptable salt thereof.

A preferred group of the peptides of formula (I), denoted Group E, are those peptides wherein at least one of A^4 and A^{28} is β -Ala, Gaba or Ava, or a pharmaceutically acceptable salt thereof.

A preferred group of the Group E peptides, denoted Group F, are those
25 peptides wherein at least one of A^4 and A^{28} is β -Ala; or a pharmaceutically acceptable salt thereof.

A preferred group of the Group E peptides, denoted Group G, are those peptides wherein A^{28} is Gaba or Ava, or a pharmaceutically acceptable salt thereof.

A preferred group of the peptides of formula (I), denoted Group H, are
30 those peptides wherein at least one of A^{18} , A^{24} , A^{25} and A^{37} is Aib, or a pharmaceutically acceptable salt thereof.

A preferred group of the peptides of formula (I), denoted Group I, are those peptides wherein at least one of A^{16} , A^{25} and A^{33} is Glu, or a pharmaceutically acceptable salt thereof.

35 A preferred group of the peptides of formula (I), denoted Group J, are those peptides wherein A^{38} is Lys-N- ϵ -octadecanoyl.

A preferred group of the Group C peptides, denoted Group K, are [A5c⁵] hPACAP(1-38)NH₂, [A5c¹⁹] hPACAP(1-38)NH₂, [Leu¹⁷, A5c¹⁹] hPACAP(1-38)NH₂, [Nle¹⁷, A5c¹⁹] hPACAP(1-38)NH₂, [N- α -octadecanoyl-His¹, A5c¹⁹] hPACAP(1-38)NH₂, [A5c¹⁹, (Lys-N- ϵ -octadecanoyl)³⁸] hPACAP(1-38)NH₂ and [A5c¹⁸] hPACAP(1-38)NH₂.

A preferred group of the Group D peptides, denoted Group L, are [A6c^{23,27}] hPACAP(1-38)NH₂, [A6c¹⁷] hPACAP(1-38)NH₂, [A6c^{19,23}] hPACAP(1-38)NH₂, [A6c²³] hPACAP(1-38)NH₂, [A6c²⁷] hPACAP(1-38)NH₂, [A6c²⁸] hPACAP(1-38)NH₂, [A6c³⁵] hPACAP(1-38)NH₂ and [A6c¹⁹] hPACAP(1-38)NH₂.

10 A preferred group of the Group F peptides, denoted Group M, are [β -Ala²⁸] hPACAP(1-38)NH₂, [A5c¹⁹, β -Ala²⁸] hPACAP(1-38)NH₂ and [β -Ala⁴] hPACAP(1-38)NH₂.

A preferred group of the Group G peptides, denoted Group N, are [Gaba²⁸] hPACAP(1-38)NH₂ and [Ava²⁸] hPACAP(1-38)NH₂.

15 A preferred group of the Group H peptides, denoted Group O, are [Aib³⁷] hPACAP(1-38)NH₂, [Aib²⁴, A6c²⁷] hPACAP(1-38)NH₂, [Aib¹⁸, A6c²³] hPACAP(1-38)NH₂, [Aib^{18,25}, A6c²³] hPACAP(1-38)NH₂ and [A6c²³, Aib²⁵] hPACAP(1-38)NH₂.

A preferred group of the Group I peptides, denoted Group P, are [Glu¹⁶] hPACAP(1-38)NH₂, [Glu³³] hPACAP(1-38)NH₂, [Aib²⁴, Glu²⁵] hPACAP(1-38)NH₂ and [Glu³³, A6c³⁵] hPACAP(1-38)NH₂.

In another aspect, this invention is directed to a pharmaceutical composition comprising an effective amount of a peptide of formula (I) as described hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

In yet another aspect, this invention is directed to a method of treating cerebrovascular ischemia, male impotence, motor neuron disease, neuropathy, pain, depression, anxiety disorders, brain trauma, memory impairments, dementia, cognitive disorder, central nervous system diseases, migraine, neurodegenerative diseases, ischemic heart disease, myocardial infarction, fibrosis, restenosis, diabetes mellitus, muscle disease, gastric ulcer, stroke, atherosclerosis, hypertension, septic shock, thrombosis, retina disease, cardiovascular disease, renal failure or cardiac failure or preventing neuronal cell death in a mammal in need thereof, which comprises administering to said mammal an effective amount of a peptide of formula (I) as described hereinabove or a pharmaceutically acceptable salt thereof.

A preferred method of the immediately foregoing method is where the central nervous system disease treated is Parkinson's disease or Alzheimer's disease.

In still another aspect, this invention provides a method of binding PACAP receptors in a mammal in need thereof, which comprises administering to said mammal an effective amount of a peptide of formula (I) or a pharmaceutically acceptable salt thereof.

In a further aspect, this invention provides a method of eliciting an agonist effect from a PACAP receptor in a mammal in need thereof, which comprises administering to said mammal an effective amount of a peptide of formula (I) or a pharmaceutically acceptable salt thereof.

Detailed Description of the Invention

With the exception of the N-terminal amino acid, all abbreviations (e.g., Ala for A₁) of amino acids in this disclosure stand for the structure of -NH-CH(R)-CO-, wherein R in the immediately foregoing formula is the side chain of an amino acid (e.g., CH₃ for Ala). For the N-terminal amino acid, the abbreviation stands for the structure of (R¹R²)-N-CH(R)-CO-, wherein R is a side chain of an amino acid and R¹ and R² are as defined above.

The following are abbreviations of certain α -amino acids: β -Nal= β -(2-naphthyl)alanine; Nle= norleucine; Cha= cyclohexylalanine; Nva= norvaline; Amp= 4-amino-phenylalanine; Pal= β -(3-pyridinyl)alanine; Aib= α -aminoisobutyric acid; hSer= homoserine; β -Ala= β -alanine; Gaba= γ -aminobutyric acid; Ava= 5-aminovaleric acid; and Abu= α -aminobutyric acid.

What is meant by Acc is the general abbreviation for a cycloalkyl amino acid which includes but is not limited to: 1-amino-1-cyclopropanecarboxylic acid (A3c); 1-amino-1-cyclobutanecarboxylic acid (A4c); 1-amino-1-cyclopentanecarboxylic acid (A5c); 1-amino-1-cyclohexane-carboxylic acid (A6c); 1-amino-1-cycloheptanecarboxylic acid (A7c); 1-amino-1-cyclooctanecarboxylic acid (A8c); and 1-amino-1-cyclononanecarboxylic acid (A9c). The terms hydroxyalkyl, hydroxyphenylalkyl, and hydroxynaphthylalkyl is intended to mean that there can be one or more hydroxy substituents on the alkyl group and/or the phenyl and naphthyl group. COX² stands for

-(C=O)X², examples of -(C=O)X² include acetyl and phenylpropionyl. What is meant by "(C₁-C₃₀) hydrocarbon moiety" is an alkyl group, an alkenyl group or an alkynyl group, where in the instance of an alkenyl or alkynyl group it is understood that a minimum of two carbons must be present.

A peptide of this invention is also denoted herein by another format, e.g., $[\beta\text{-Ala}^{28}]\text{hPACAP}(1\text{-}38)\text{NH}_2$, with the substituted amino acids from the natural sequence placed between the set of brackets (e.g., $\beta\text{-Ala}^{28}$ for Gly^{28} in hPACAP). The abbreviation hPACAP stands for human PACAP. The numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hPACAP(1-38) is amino acids 1 through 38 of the peptide sequence for human PACAP). The sequence for hPACAP(1-38) is listed in Christophe, J., et al., Biochimica et Biophysica Acta, 1154, 183-199, (1993). The designation "NH₂" in PACAP(1-38)NH₂ indicates that the C-terminus of the peptide is amidated. PACAP(1-38), on the other hand, has a free acid C-terminus.

The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids).

As is well known to those skilled in the art, the known and potential uses of PACAP is varied and multitudinous [See Arimura, A., Regulatory Peptides, 37, (1992), 287-303; Christophe, J., Biochimica et Biophysica Acta, 1154, (1993), 183-199; Arimura, A. and Shioda, S., Frontiers in Neuroendocrinology, 16, 53-88 (1995)]. Thus, the administration of the compounds of this invention for purposes of eliciting an agonist effect can have the same effects and uses as PACAP itself. These varied uses of PACAP may be summarized as follows: cerebrovascular ischemia, Alzheimer's disease, male impotence, motor neuron disease, neuropathy, pain, depression, anxiety disorders, brain trauma, memory impairments, dementia, cognitive disorder, central nervous system diseases (such as Parkinson's disease, Alzheimer's disease), migraine, neurodegenerative diseases, prevention of neuronal cell death, ischemic heart disease, myocardial infarction, fibrosis, restenosis, diabetes mellitus, muscle disease, gastric ulcer, stroke, atherosclerosis, hypertension, septic shock, thrombosis, retina disease, cardiovascular disease, renal failure and cardiac failure.

Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula I in association with a pharmaceutically acceptable carrier.

The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such

that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 0.00001 to 200 mg/kg/day, preferably 0.001 to 100 mg/kg/day, which can be
5 administered as a single dose or divided into multiple doses.

The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms
10 appropriate for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional
15 substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration include pharmaceutically
20 acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administration
25 include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by,
30 for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.

Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.

Compositions for nasal or sublingual administration are also prepared with 5 standard excipients well known in the art.

Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches 10 sustained release compositions comprising a bioactive agent in a gelable form. U.S. Application No. 08/929,363 filed September 9, 1997, teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Application No. 08/740,778 filed November 1, 1996, teaches sustained release compositions comprising a bioactive agent and cyclodextrin. U.S. Application No. 09/015,394 filed 15 January 29, 1998, teaches absorbable sustained release compositions of a bioactive agent. The teachings of the foregoing patents and applications are incorporated herein by reference.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art 20 to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference.

In vitro assays: A compound of the instant invention can be tested for its ability to bind to PACAP type I and type II receptors according to the following procedure.

25 Cell Culture: Rat AR42J pancreas cells (ATCC, Rockville, MD), expressing the PACAP-I receptor, were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, and maintained at 37 °C in a humidified atmosphere of 5% CO₂/95% air.

Animals: Male rats (Taconic, Germantown, NY) were sacrificed by 30 decapitation and the livers were obtained and used as the source of the PACAP-II receptor.

Radioligand Binding: Membranes were prepared for radioligand binding studies by homogenization of the AR42J cells (for PACAP-I receptor) or rat liver (for PACAP-II receptor) in 20 ml of ice-cold 50 mM Tris-HCl with a Brinkman Polytron 35 (Brinkman, Westbury, NY) (setting 6, 15 sec). The homogenates were washed twice by centrifugation (39,000 g / 10 min), and the final pellets were resuspended in 50

mM Tris-HCl, containing 2.5 mM MgCl_2 , 0.1 mg/ml bacitracin (Sigma Chemical, St. Louis, MO), and 0.1% BSA. For assay, aliquots (0.4 ml) were incubated with 0.05 nM [^{125}I]PACAP-27 (2200 Ci/mmol, New England Nuclear, Boston, MA), with and without 0.05 ml of unlabeled competing test compound. After a 40 min incubation (25 °C), the bound [^{125}I]PACAP-27 was separated from the free [^{125}I]PACAP-27 by rapid filtration through GF/B filters (Brandel, Gaithersburg, MD), which had been previously soaked in 0.3% polyethyleneimine. The filters were then washed three times with 5-ml aliquots of ice-cold 50 mM Tris-HCl, and the bound radioactivity trapped on the filters was counted by gamma spectrometry (Wallac LKB, Gaithersburg, MD). Specific binding to either the Type I receptor or the Type II receptor was defined as the total [^{125}I]PACAP-27 bound minus that bound in the presence of 1000 nM PACAP-27 (Bachem, Torrance, CA).

Synthesis

The peptides of the present invention can be prepared by standard solid phase synthesis. See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984). The following is a description of how [$\beta\text{-Ala}^{28}$]hPACAP(1-38) NH_2 was prepared. Other peptides of the present invention can be prepared in an analogous manner by a person of ordinary skill in the art as enabled by the teachings herein.

Preparation of a pharmaceutically-acceptable salt of a peptide of the present invention is well known to those of ordinary skill in the art. For example, the HCl salt of a peptide can be made by dissolving the peptide in water and adding the appropriate amount of a weak aqueous solution of HCl and then lyophilizing the solution. Other salts may be made in a similar manner or by other methods known to those skilled in the art, such as salt exchange.

Example 1

[$\beta\text{-Ala}^{28}$]hPACAP(1-38) NH_2

The title peptide was synthesized on an Applied Biosystems (Foster City, CA) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnoize, et al., Int. J. Peptide Protein Res., 90:180 (1992). 4-Methylbenzhydrylamine (MBHA) resin (Peninsula, Belmont, CA) with the substitution of 0.93 mmol/g was used. The Boc amino acids (Bachem, CA, Torrance, CA; Nova Biochem., LaJolla, CA) were used with the following side chain protection: Boc-Ala-OH, Boc-Arg(Tos)-OH, Boc-Asp(OcHex)-OH, Boc-Tyr(2BrZ)-OH, Boc-His(DNP)-OH, Boc-Val-OH, Boc-Leu-OH, Boc-Gly-OH, Boc-Gln-OH, Boc-Ile-OH, Boc-Lys(2ClZ)-OH, Boc-Thr(Bzl)-OH, Boc-Ser(Bzl)-OH; Boc-Phe-OH, Boc-Met-

OH and Boc- β -Ala-OH. The synthesis was carried out on a 0.14 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2 x 1 min. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt.

At the end of the assembly of the peptide chain, the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2 x 30 min. to remove the DNP group on the His side chain. The N-terminal Boc group was then removed by treatment with 100% TFA for 2 x 2 min. The partially-deprotected peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (24 mg) at 0°C for 75 min. HF was removed by a flow of nitrogen. The residue was washed with ether (6 x 10 mL) and extracted with 4N HOAc (6 x 10 mL).

The peptide mixture in the aqueous extract was purified on a reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VydacTM C₁₈ column (Nest Group, Southborough, MA). The column was eluted with a linear gradient (10% to 45% of solution B over 130 min.) at a flow rate of 10 mL/min (Solution A = water containing 0.1% TFA; Solution B = acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 286 mg of a white solid was obtained. Purity was >99% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 4548.5 (in agreement with the calculated molecular weight of 4548.4).

The synthesis of other analogues of the present invention were carried out in the same manner as described for the synthesis of [β -Ala²⁸]hPACAP(1-38)NH₂ above but using the appropriate protected amino acids.

The protected amino acid 1-[N-tert-butoxycarbonyl-amino]-1-cyclohexanecarboxylic acid (Boc-A6c-OH) was synthesized as follows. 19.1 g (0.133 mol) of 1-amino-1-cyclohexanecarboxylic acid (Acros Organics, Fisher Scientific, Pittsburgh, PA) was dissolved in 200 ml of dioxane and 100 ml of water. To it was added 67 mL of 2N NaOH. The solution was cooled in an ice-water bath. 32.0 g (0.147 mol) of di-tert-butyl-dicarbonate was added to this solution. The reaction mixture was stirred overnight at room temperature. Dioxane was then removed under reduced pressure. 200 ml of ethyl acetate was added to the remaining aqueous solution. The mixture was cooled in an ice-water bath. The pH of the aqueous layer was adjusted to about 3 by adding 4N HCl. The organic layer was separated. The aqueous layer was

extracted with ethyl acetate (1 x 100 ml). The two organic layers were combined and washed with water (2 x 150 ml), dried over anhydrous MgSO_4 , filtered, and concentrated to dryness under reduced pressure. The residue was recrystallized in ethyl acetate/hexanes. 9.2 g of the pure product was obtained. 29% yield.

5 Boc-A5c-OH was synthesized in an analogous manner to that of Boc-A6c-OH. Other protected Acc amino acids can be prepared in an analogous manner by a person of ordinary skill in the art as enabled by the teachings herein.

In the synthesis of a PACAP analogue of this invention containing A5c, A6c and/or Aib, the coupling time was 2 hrs. for these residues and the immediate residue
10 following them.

The full names for the abbreviations used above are as follows: Boc for t-butyloxycarbonyl, HF for hydrogen fluoride, Fm for formyl, Xan for xanthyl, Bzl for benzyl, Tos for tosyl, DNP for 2,4-dinitrophenyl, DMF for dimethylformamide, DCM for dichloromethane, HBTU for 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium
15 hexafluorophosphate, DIEA for diisopropylethylamine, HOAc for acetic acid, TFA for trifluoroacetic acid, 2ClZ for 2-chlorobenzyloxycarbonyl, 2BrZ for 2-bromobenzyloxycarbonyl and OcHex for O-cyclohexyl.

The substituents R^1 and R^2 of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art.
20 For example, alkyl groups, e.g., $(\text{C}_1\text{-C}_{30})$ alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., C_{1-12} hydroxyalkyl, may also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COX^1 , may be attached by coupling the free acid, e.g., X^1COOH , to the free amine of the N-terminal amino acid by mixing the completed resin with 3
25 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for about one hour. If the free acid contains a free hydroxy group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBT.

Examples 2-29

30 Examples 2-30 were synthesized according to the method described in Example 1 using the appropriately protected amino acid.

Example	Formula	Mass Spec.*	Calculated M.W.
2	$[\text{A6c}^{23,27}]\text{hPACAP}(1\text{-}38)\text{NH}_2$	4559.2	4558.7
3	$[\text{Aib}^{37}]\text{hPACAP}(1\text{-}38)\text{NH}_2$	4505.5	4505.4

			14	
	4	[A6c ¹⁷] hPACAP(1-38)NH ₂	4527.8	4528.3
	5	[A6c ^{19,23}] hPACAP(1-38)NH ₂	4571.1	4572.4
	6	[A6c ²³] hPACAP(1-38)NH ₂	4546.4	4546.4
	7	[Aib ¹⁸ , A6c ²³] hPACAP(1-38)NH ₂	4560.3	4560.4
5	8	[Aib ^{18,25} , A6c ²³] hPACAP(1-38)NH ₂	4574.8	4574.4
	9	[Aib ²⁴ , A6c ²⁷] hPACAP(1-38)NH ₂	4560.7	4560.4
	10	[A6c ²³ , Aib ²⁵] hPACAP(1-38)NH ₂	4560.7	4560.4
	11	[A6c ²⁷] hPACAP(1-38)NH ₂	4547.0	4546.4
	12	[Glu ¹⁶] hPACAP(1-38)NH ₂	4535.2	4535.3
10	13	[Glu ³³] hPACAP(1-38)NH ₂	4535.2	4535.3
	14	[Aib ²⁴ , Glu ²⁵] hPACAP(1-38)NH ₂	4605.6	4606.4
	15	[Glu ³³ , A6c ³⁵] hPACAP(1-38)NH ₂	4561.9	4561.4
	16	[A6c ³⁵] hPACAP(1-38)NH ₂	4560.4	4560.4
	17	[A6c ²⁸] hPACAP(1-38)NH ₂	4602.1	4602.5
15	18	[A5c ⁵] hPACAP(1-38)NH ₂	4532.3	4532.3
	19	[A5c ¹⁹] hPACAP(1-38)NH ₂	4546.4	4546.4
	20	[A5c ¹⁹ , β-Ala ²⁸] hPACAP(1-38)NH ₂	4559.8	4560.4
	21	[GABA ²⁸] hPACAP(1-38)NH ₂	4562.3	4562.4
	22	[Leu ¹⁷ , A5c ¹⁹] hPACAP(1-38)NH ₂	4528.0	4528.3
20	23	[Nle ¹⁷ , A5c ¹⁹] hPACAP(1-38)NH ₂	4527.2	4528.3
	24	[A5c ¹⁸] hPACAP(1-38)NH ₂	4573.9	4574.4
	25	[β-Ala ⁴] hPACAP(1-38)NH ₂	4547.3	4548.4
	26	[A6c ¹⁹] hPACAP(1-38)NH ₂	4559.3	4560.4

Example	Formula	Mass Spec.*	Calculated M.W.
27	[Ava ²⁸] hPACAP(1-38)NH ₂	4575.3	4576.4
28	[(N- α -octadecanoyl-His) ¹ , A5c ¹⁹] hPACAP(1-38)NH ₂	4812.1	4812.8
5 29	[A5c ¹⁹ , (Lys-N- ϵ -octadecanoyl) ³⁸] hPACAP(1-38)NH ₂	4812.2	4812.8

*Mass spec was taken on a Finnigan Mat SSQ 7000, Electrospray Ionization Mass Spectrometry

16
CLAIMS

1. A peptide of formula (I),

$$(R^1 R^2) A^1 - A^2 - A^3 - A^4 - A^5 - A^6 - A^7 - A^8 - A^9 - A^{10} - A^{11} - A^{12} - A^{13} - A^{14} - A^{15} - A^{16} - A^{17} - A^{18} - A^{19} - A^{20} - A^{21} - A^{22} - A^{23} - A^{24} - A^{25} - A^{26} - A^{27} - A^{28} - A^{29} - A^{30} - A^{31} - A^{32} - A^{33} - A^{34} - A^{35} - A^{36} - A^{37} - A^{38} - R^3$$

(I),

or a pharmaceutically acceptable salt thereof, wherein,

A^1 is His or Pal;

A^2 is Ser, Thr or hSer;

A^3 is Asp or Glu;

A^4 is Gly, β -Ala, Gaba, Ava, Aib, Acc or $HN-(CH_2)_m-C(O)$;

A^5 is Ile, Leu, Cha, Nle, Val, Tle, Abu, Aib, Acc or Nva;

A^6 is Phe, p-X-Phe, β -Nal, Cha, Tyr, Trp, Acc or Aib;

A^7 is Thr, Ser or Val;

A^8 is Asp or Glu;

A^9 is Ser, Thr or hSer;

A^{10} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp or Acc;

A^{11} is Ser, Thr or hSer;

A^{12} , A^{14} and A^{15} are each independently selected from the group consisting of Arg, Lys, Orn, hArg and $HN-CH((CH_2)_n-NH-R^4)-C(O)$;

A^{13} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp or Acc;

A^{16} is Gln, Glu, Asp or Asn;

A^{17} is Met, Leu, Nle, Abu, Tle, Val, Ile, Cha, Ala, Aib, Acc or Nva;

A^{18} is Ala, Aib or Acc;

A^{19} is Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Acc, Nle or Nva;

A^{20} , A^{21} , A^{29} , A^{30} , A^{32} , A^{34} , A^{36} and A^{38} are each independently selected from the group consisting of Lys, Arg, Orn, hArg and $HN-CH((CH_2)_n-NH-R^4)-C(O)$ or is deleted;

A^{22} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp, Acc or is deleted;

A^{23} is Leu, Ile, Nle, Tle, Met, Val, Ala, Aib, Acc, Cha, Phe, p-X-Phe, Abu, Nva or is deleted;

A^{24} is Ala, Aib, Val, Abu, Acc, Ile, Leu, Nle, Tle, Nva or is deleted;

A^{25} is Ala, Glu, Aib, Val, Abu, Acc, Ile, Leu, Nle, Nva, Tle or is deleted;

A^{26} is Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Acc, Nva, Nle or is deleted;

A^{27} is Leu, Ile, Nle, Tle, Met, Val, Ala, Aib, Acc, Nva, Cha, Phe, p-X-Phe, Abu or is deleted;

A^{28} is Gly, Aib, Acc, β -Ala, Gaba, Ava, $HN-(CH_2)_m-C(O)$ or is deleted;

A^{31} is Tyr, p-X-Phe, Phe, Amp, β -Nal, Trp, Acc or is deleted;

A³³ is Gln, Asn, Glu, Asp or is deleted;

A³⁵ is Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Nva, Acc, Nle or is deleted;

A³⁷ is Asn, Gln, Asp, Glu, Ala, Aib, Acc or is deleted;

R¹ and R² are each independently selected from the group consisting of H, (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl-(C₁-C₃₀)alkyl, naphthyl-(C₁-C₃₀)alkyl, hydroxy-(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxy-phenyl-(C₁-C₃₀)alkyl or hydroxy-naphthyl-(C₁-C₃₀)alkyl;

or one of R¹ or R² is COX² where X² is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl-(C₁-C₃₀)alkyl, naphthyl-(C₁-C₃₀)alkyl, hydroxy-(C₁-C₃₀)alkyl, hydroxy-(C₂-C₃₀)alkenyl, hydroxy-phenyl-(C₁-C₃₀)alkyl or hydroxy-naphthyl-(C₁-C₃₀)alkyl;

R³ is OH, NH₂, (C₁-C₃₀)alkoxy or NH-Y-CH₂-Z, where Y is a (C₁-C₃₀) hydrocarbon moiety and Z is CO₂H or CONH₂;

where X for each occurrence is independently selected from the group consisting of OH, OCH₃, F, Cl, Br and CH₃;

m for each occurrence is independently an integer from 5-10;

n for each occurrence is independently an integer from 1-5; and

R⁴ for each occurrence is independently (C₁-C₃₀)alkyl, (C₁-C₃₀)acyl or -C((NH)(NH₂)).

2. A peptide according to claim 1, wherein at least one of A⁵, A¹⁷, A¹⁸, A¹⁹, A²³, A²⁷, A²⁸ and A³⁵ is Acc, or a pharmaceutically acceptable salt thereof.

3. A peptide according to claim 2, wherein at least one of A⁵, A¹⁷, A¹⁸, A¹⁹, A²³, A²⁷, A²⁸ and A³⁵ is A6c or A5c, or a pharmaceutically acceptable salt thereof.

4. A peptide according to claim 3, wherein at least one of A⁵, A¹⁸ and A¹⁹ is A5c, or a pharmaceutically acceptable salt thereof.

5. A peptide according to claim 3, wherein at least one of A¹⁷, A¹⁹, A²³, A²⁷, A²⁸ and A³⁵ is A6c, or a pharmaceutically acceptable salt thereof.

6. A peptide according to claim 1, wherein at least one of A⁴ and A²⁸ is β -Ala, Gaba or Ava, or a pharmaceutically acceptable salt thereof.

7. A peptide according to claim 6, wherein at least one of A⁴ and A²⁸ is β -Ala; or a pharmaceutically acceptable salt thereof.

8. A peptide according to claim 6, wherein A²⁸ is Gaba or Ava, or a pharmaceutically acceptable salt thereof.

9. A peptide according to claim 1, wherein at least one of A¹⁸, A²⁴, A²⁵ and A³⁷ is Aib, or a pharmaceutically acceptable salt thereof.

10. A peptide according to claim 1, wherein at least one of A¹⁶, A²⁵ and A³³ is Glu, or a pharmaceutically acceptable salt thereof.

11. A peptide according to claim 1, wherein A³⁸ is Lys-N- ϵ -octadecanoyl.
12. A peptide according to claim 4, wherein said peptide is [A5c⁵] hPACAP(1-38)NH₂, [A5c¹⁹] hPACAP(1-38)NH₂, [Leu¹⁷, A5c¹⁹] hPACAP(1-38)NH₂,
5 [Nle¹⁷, A5c¹⁹] hPACAP(1-38)NH₂, [N- α -octadecanoyl-His¹, A5c¹⁹] hPACAP(1-38)NH₂, [A5c¹⁹, (Lys-N- ϵ -octadecanoyl)³⁸] hPACAP(1-38)NH₂ or [A5c¹⁸] hPACAP(1-38)NH₂.
13. A peptide according to claim 5 wherein said peptide is [A6c^{23,27}] hPACAP(1-38)NH₂, [A6c¹⁷] hPACAP(1-38)NH₂, [A6c^{19,23}] hPACAP(1-38)NH₂, [A6c²³]
10 hPACAP(1-38)NH₂, [A6c²⁷] hPACAP(1-38)NH₂, [A6c²⁸] hPACAP(1-38)NH₂, [A6c³⁵] hPACAP(1-38)NH₂ or [A6c¹⁹] hPACAP(1-38)NH₂.
14. A peptide according to claim 7, wherein said peptide is [β -Ala²⁸] hPACAP(1-38)NH₂, [A5c¹⁹, β -Ala²⁸] hPACAP(1-38)NH₂ or [β -Ala⁴] hPACAP(1-38)NH₂.
- 15 15. A peptide according to claim 8, wherein said peptide is [Gaba²⁸] hPACAP(1-38)NH₂ or [Ava²⁸] hPACAP(1-38)NH₂.
16. A peptide according to claim 9, wherein said peptide is [Aib³⁷] hPACAP(1-38)NH₂, [Aib²⁴, A6c²⁷] hPACAP(1-38)NH₂, [Aib¹⁸, A6c²³] hPACAP(1-38)NH₂, [Aib^{18,25}, A6c²³] hPACAP(1-38)NH₂ or [A6c²³, Aib²⁵] hPACAP(1-38)NH₂.
- 20 17. A peptide according to claim 10, wherein said peptide is [Glu¹⁶] hPACAP(1-38)NH₂, [Glu³³] hPACAP(1-38)NH₂, [Aib²⁴, Glu²⁵] hPACAP(1-38)NH₂ or [Glu³³, A6c³⁵] hPACAP(1-38)NH₂.
18. A pharmaceutical composition comprising an effective amount of a peptide according to claim 1 or a pharmaceutically acceptable salt thereof and a
25 pharmaceutically acceptable carrier.
19. A method of treating cerebrovascular ischemia, male impotence, motor neuron disease, neuropathy, pain, depression, anxiety disorders, brain trauma, memory impairments, dementia, cognitive disorder, central nervous system diseases, migraine, neurodegenerative diseases, ischemic heart disease, myocardial infarction,
30 fibrosis, restenosis, diabetes mellitus, muscle disease, gastric ulcer, stroke, atherosclerosis, hypertension, septic shock, thrombosis, retina disease, cardiovascular disease, renal failure or cardiac failure or preventing neuronal cell death in a mammal in need thereof, which comprises administering to said mammal an effective amount of a peptide according to claim 1 or a pharmaceutically acceptable salt thereof.
- 35 20. A method according to claim 19 wherein the central nervous system disease is Parkinson's disease or Alzheimer's disease.

21. A method of binding a PACAP receptor in a mammal in need thereof, which comprises administering to said mammal an effective amount of a peptide according to claim 1 or a pharmaceutically acceptable salt thereof.

22. A method of eliciting an agonist effect from a PACAP receptor in
5 a mammal in need thereof, which comprises administering to said mammal an effective amount of a peptide according to claim 1 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/03020

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/575 A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 09064 A (ARIMURA AKIRA ;UNIV TULANE (US)) 28 March 1996 (1996-03-28) abstract; claims page 2, paragraph 1 ---	1,18-22
X	EP 0 404 652 A (UNIV TULANE) 27 December 1990 (1990-12-27) claims ---	1,18-22
X	EP 0 529 487 A (TAKEDA CHEMICAL INDUSTRIES LTD) 3 March 1993 (1993-03-03) claims ---	1,18-22
X	EP 0 796 867 A (ITOHAM FOODS INC) 24 September 1997 (1997-09-24) abstract; claims --- -/--	1,18-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

28 October 1999

Date of mailing of the international search report

04/11/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

Inter	onal Application No
PCT/EP 99/03020	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 249 434 A (SPOFA VEREINIGTE PHARMA WERKE) 16 December 1987 (1987-12-16) ----	
A	WO 98 30590 A (BIOMEASURE INC ;DONG ZHENG XIN (US)) 16 July 1998 (1998-07-16) -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/ 03020

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 19-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/03020

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9609064 A	28-03-1996	WO 9609318 A AU 3681095 A	28-03-1996 09-04-1996
EP 0404652 A	27-12-1990	US 5128242 A CA 2018714 A JP 2897169 B JP 3123798 A	07-07-1992 19-12-1990 31-05-1999 27-05-1991
EP 0529487 A	03-03-1993	AT 176243 T CA 2076593 A DE 69228277 D DE 69228277 T JP 5194595 A US 5801147 A US 5623050 A	15-02-1999 23-02-1993 11-03-1999 08-07-1999 03-08-1993 01-09-1998 22-04-1997
EP 0796867 A	24-09-1997	JP 8333276 A JP 9100237 A AU 682638 B AU 5911296 A US 5856303 A CA 2196308 A WO 9641814 A	17-12-1996 15-04-1997 09-10-1997 09-01-1997 05-01-1999 27-12-1996 27-12-1996
EP 0249434 A	16-12-1987	CS 8604332 A AT 105300 T CA 1308515 A DE 3789729 D DE 3789729 T JP 2089563 C JP 8002916 B JP 63003000 A US 4898930 A	12-08-1992 15-05-1994 06-10-1992 09-06-1994 18-08-1994 02-09-1996 17-01-1996 07-01-1988 06-02-1990
WO 9830590 A	16-07-1998	US 5955574 A AU 5519998 A EP 0948541 A NO 993341 A ZA 9800061 A	21-09-1999 03-08-1998 13-10-1999 06-09-1999 07-07-1998